Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 5 completed trials

    Completion Rate
    100%(5/5)
    Active Trials
    0(0%)
    Results Posted
    20%(1 trials)

    Phase Distribution

    Phase 1
    1
    20%
    Phase 3
    1
    20%
    Not Applicable
    3
    60%

    Phase Distribution

    1

    Early Stage

    0

    Mid Stage

    1

    Late Stage

    Phase Distribution5 total trials
    Phase 1Safety & dosage
    1(20.0%)
    Phase 3Large-scale testing
    1(20.0%)
    N/ANon-phased studies
    3(60.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    5 of 5 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Completed(5)

    Detailed Status

    Completed5

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 11 (20.0%)
    Phase 31 (20.0%)
    N/A3 (60.0%)

    Trials by Status

    completed5100%

    Recent Activity

    0 active trials
    Showing 5 of 5
    completedphase_3

    Estrogen and Fear in PTSD

    NCT04192266
    completednot_applicable

    Psychotherapy for Psychosis, Adverse Events, and Substance Misuse

    NCT04546178
    completedphase_1

    Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder

    NCT00895518
    completednot_applicable

    Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes

    NCT00229307
    completednot_applicable

    Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients

    NCT00229372

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT04192266Phase 3

    Estrogen and Fear in PTSD

    Completed
    NCT04546178Not Applicable

    Psychotherapy for Psychosis, Adverse Events, and Substance Misuse

    Completed
    NCT00895518Phase 1

    Examining the Effectiveness of an Early Psychological Intervention to Prevent Post-Traumatic Stress Disorder

    Completed
    NCT00229307Not Applicable

    Prolonged Exposure (PE) Treatment for Post Traumatic Stress Disorder (PTSD) 20 Minutes Versus 40 Minutes

    Completed
    NCT00229372Not Applicable

    Prolonged Exposure Versus Treatment as Usual in Chronic Posttraumatic Stress Disorder Combat and Terror Related Patients

    Completed

    All 5 trials loaded

    Drug Details

    Intervention Type
    Behavioral
    Total Trials
    5